411 related articles for article (PubMed ID: 31099134)
21. A novel microRNA signature predicts survival in stomach adenocarcinoma.
Ding B; Gao X; Li H; Liu L; Hao X
Oncotarget; 2017 Apr; 8(17):28144-28153. PubMed ID: 28423653
[TBL] [Abstract][Full Text] [Related]
22. miR-1301-3p suppresses tumor growth by downregulating PCNA in thyroid papillary cancer.
Qiao DH; He XM; Yang H; Zhou Y; Deng X; Cheng L; Zhou XY
Am J Otolaryngol; 2021; 42(2):102920. PubMed ID: 33454555
[TBL] [Abstract][Full Text] [Related]
23. Tumor Mutation Burden Predicts Relapse in Papillary Thyroid Carcinoma With Changes in Genes and Immune Microenvironment.
Guo M; Chen Z; Li Y; Li S; Shen F; Gan X; Feng J; Cai W; Liu Q; Xu B
Front Endocrinol (Lausanne); 2021; 12():674616. PubMed ID: 34248843
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis.
Liu N; Chen NY; Cui RX; Li WF; Li Y; Wei RR; Zhang MY; Sun Y; Huang BJ; Chen M; He QM; Jiang N; Chen L; Cho WC; Yun JP; Zeng J; Liu LZ; Li L; Guo Y; Wang HY; Ma J
Lancet Oncol; 2012 Jun; 13(6):633-41. PubMed ID: 22560814
[TBL] [Abstract][Full Text] [Related]
25. Circular RNA profiling reveals a potential role of hsa_circ_IPCEF1 in papillary thyroid carcinoma.
Guo M; Sun Y; Ding J; Li Y; Yang S; Zhao Y; Jin X; Li SS
Mol Med Rep; 2021 Aug; 24(2):. PubMed ID: 34165176
[TBL] [Abstract][Full Text] [Related]
26. Comprehensive MicroRNA expression profiling identifies novel markers in follicular variant of papillary thyroid carcinoma.
Dettmer M; Perren A; Moch H; Komminoth P; Nikiforov YE; Nikiforova MN
Thyroid; 2013 Nov; 23(11):1383-9. PubMed ID: 23427895
[TBL] [Abstract][Full Text] [Related]
27. Downregulation of miR-519d-3p is Associated with Poor Outcomes and Facilitates Tumor Progression in Papillary Thyroid Cancer by Regulating FOXQ1.
Li P; Pan X; Zheng Z; Sun Y; Han Y; Dong J; Lu M
Horm Metab Res; 2021 Sep; 53(9):625-632. PubMed ID: 34496413
[TBL] [Abstract][Full Text] [Related]
28. Identifying the tumor-progressive gene expression profile in high-risk papillary thyroid cancer.
Shibata M; Inaishi T; Ichikawa T; Shimizu D; Soeda I; Takano Y; Takeuchi D; Tsunoda N; Kikumori T
Surg Today; 2021 Oct; 51(10):1703-1712. PubMed ID: 33733290
[TBL] [Abstract][Full Text] [Related]
29. Integrated analysis identifying new lncRNA markers revealed in ceRNA network for tumor recurrence in papillary thyroid carcinoma and build of nomogram.
Chen F; Li Z; Deng C; Yan H
J Cell Biochem; 2019 Dec; 120(12):19673-19683. PubMed ID: 31271223
[TBL] [Abstract][Full Text] [Related]
30. MicroRNA-based molecular classification of papillary thyroid carcinoma.
Rosignolo F; Memeo L; Monzani F; Colarossi C; Pecce V; Verrienti A; Durante C; Grani G; Lamartina L; Forte S; Martinetti D; Giuffrida D; Russo D; Basolo F; Filetti S; Sponziello M
Int J Oncol; 2017 May; 50(5):1767-1777. PubMed ID: 28393181
[TBL] [Abstract][Full Text] [Related]
31. Identification of Prognostic Biomarkers in Papillary Thyroid Cancer and Developing Non-Invasive Diagnostic Models Through Integrated Bioinformatics Analysis.
Oskouie AA; Ahmadi MS; Taherkhani A
Microrna; 2022; 11(1):73-87. PubMed ID: 35068400
[TBL] [Abstract][Full Text] [Related]
32. A four-miRNA signature as a novel biomarker for predicting survival in endometrial cancer.
Wu YS; Lin H; Chen D; Yi Z; Zeng B; Jiang Y; Ren G
Gene; 2019 May; 697():86-93. PubMed ID: 30779946
[TBL] [Abstract][Full Text] [Related]
33. Low expression of
Yang L; Zhang X; Zhang J; Liu Y; Ji T; Mou J; Fang X; Wang S; Chen J
Future Oncol; 2022 Jan; 18(3):333-348. PubMed ID: 34756116
[TBL] [Abstract][Full Text] [Related]
34. A novel gene panel for prediction of lymph-node metastasis and recurrence in patients with thyroid cancer.
Ruiz EML; Niu T; Zerfaoui M; Kunnimalaiyaan M; Friedlander PL; Abdel-Mageed AB; Kandil E
Surgery; 2020 Jan; 167(1):73-79. PubMed ID: 31711617
[TBL] [Abstract][Full Text] [Related]
35. Identification of key genes of papillary thyroid carcinoma by integrated bioinformatics analysis.
Xue G; Lin X; Wu JF; Pei D; Wang DM; Zhang J; Zhang WJ
Biosci Rep; 2020 Aug; 40(8):. PubMed ID: 32766727
[TBL] [Abstract][Full Text] [Related]
36. miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma.
Minna E; Romeo P; Dugo M; De Cecco L; Todoerti K; Pilotti S; Perrone F; Seregni E; Agnelli L; Neri A; Greco A; Borrello MG
Oncotarget; 2016 Mar; 7(11):12731-47. PubMed ID: 26871295
[TBL] [Abstract][Full Text] [Related]
37. A Novel Immune-Related Prognostic Signature for Thyroid Carcinoma.
Xue Y; Li J; Lu X
Technol Cancer Res Treat; 2020; 19():1533033820935860. PubMed ID: 32588760
[TBL] [Abstract][Full Text] [Related]
38. Identification of ferroptosis genes in immune infiltration and prognosis in thyroid papillary carcinoma using network analysis.
Lin R; Fogarty CE; Ma B; Li H; Ni G; Liu X; Yuan J; Wang T
BMC Genomics; 2021 Jul; 22(1):576. PubMed ID: 34315405
[TBL] [Abstract][Full Text] [Related]
39. New global analysis of the microRNA transcriptome of primary tumors and lymph node metastases of papillary thyroid cancer.
Saiselet M; Gacquer D; Spinette A; Craciun L; Decaussin-Petrucci M; Andry G; Detours V; Maenhaut C
BMC Genomics; 2015 Oct; 16():828. PubMed ID: 26487287
[TBL] [Abstract][Full Text] [Related]
40. Development and validation of a three-immune-related gene signature prognostic risk model in papillary thyroid carcinoma.
Gan X; Guo M; Chen Z; Li Y; Shen F; Feng J; Cai W; Xu B
J Endocrinol Invest; 2021 Oct; 44(10):2153-2163. PubMed ID: 33620716
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
